camrelizumab

Overview

Camrelizumab (SHR-1210) is a humanized anti-PD-1 (PDCD1) monoclonal antibody. It has been investigated in multiple Chinese phase II/III trials, including in combination with chemotherapy and targeted agents for R/M nasopharyngeal carcinoma (NPC).

Evidence in the corpus

  • Apatinib + camrelizumab in R/M NPC (NCT04586088, n=58): ORR 65.5%; median PFS 10.4 mo; grade ≥3 TRAE 58.6%; ICI-refractory cohort ORR 43.3% PMID:24952746.
  • CDK4/6 inhibitor dalpiciclib + camrelizumab in anti-PD-1-refractory R/M NPC (NCT05724355, n=34): ORR 32.4%; median DOR 10.4 mo; median PFS 6.7 mo; grade ≥3 TRAE 76.5% PMID:24952746.

Resistance mechanisms

Cancer types (linked)

Sources

This page was processed by entity-page-writer on 2026-05-11.